ALFA News
Straight from the exchange filing
Latest Pharmaceuticals stock news from NSE and BSE filings, 95 stories so far.
Aurobindo Pharma receives USFDA final approval for its first MDI product, targeting a US$301 million market. The approval covers Beclomethasone Inhalation Aerosol.
Sat Kartar Life Limited signs LOI for a new 20-bed hospital-cum-therapy centre in Dehradun with a ₹0.70 crore investment. Expected operational by December 2026.
Shilpa Medicare receives SEC approval for OERIS, a world-first 5-day extended-release ondansetron injection with Indian patent protection valid until 2039.
Glenmark Pharmaceuticals launches RYALTRIS nasal spray in Brazil, targeting a patient pool of 60 million. The product is now approved in 57 global markets.
Acutaas Chemicals Ltd granted a 20-year Indian process patent for 2,4-dimethylthiophenol, taking its total patent tally to 11 amid 130% annual stock growth.
IOL Chemicals and Pharmaceuticals (IOLCP) announces a ₹495 Cr expansion, adding 6,000 MTPA Ibuprofen capacity and entering the CDMO segment. Commercial by 2027.
Natco Pharma approves a ₹1,300 crore rights issue for equity shareholders and provides a key update on its demerger with Natco Crop Health Sciences Limited.
Fermenta Biotech signs an exclusive licence with VIT Vellore for Vitamin B12 fortification technology in fermented foods for its ₹1,409 crore market cap business.
Alkem Laboratories launches Renocia Exo, India's first patented Ginsenoside Exosome-based hair serum, targeting the dermatology market. Market cap ₹62,048 Cr.
Novartis India enters a ₹10 crore exclusive distribution deal with NHPL for the retina portfolio, marking its entry into India's ophthalmology therapy area.
Morepen Laboratories reaches 614 KL reactor capacity following the completion of its Phase 1 expansion ahead of schedule, targeting API and CDMO growth.
Jeena Sikho Lifecare (JSLL) launches Jeevanodya Vati and Ojavardhan Vati to expand its Ayurvedic portfolio. The company reports TTM revenue of ₹851.48 Cr.
Fredun Pharmaceuticals launches PAWTALKS, a digital platform for animal healthcare, as its net profit grows 94.1% YoY to ₹13.13 Cr in the latest quarter.
Natural Capsules Limited approves a preferential issue of equity shares and warrants totaling ₹10.01 Crore to promoters at ₹178 per share to raise capital.
Aurobindo Pharma subsidiary Lannett launches generic Advair Diskus in the US, marking its first inhalation product entry into the $908M respiratory market.
Jeena Sikho Lifecare (JSLL) launches 9 new Ayurvedic products, including Arishtas and Headache Patches, to drive growth in its high-margin wellness segment.
Lupin Limited subsidiary VISUfarma B.V. signs ₹832 Cr deal with Visus Therapeutics to commercialize YUVEZZI in Europe, targeting the presbyopia treatment market.
Wanbury Limited receives EDQM approval for Rivaroxaban API and USFDA DMF clearances for Paroxetine HCI and Metformin HCI, targeting the EU and US pharma markets.
Accent Microcell Limited initiates a 4.45 MW wind turbine project with Inox Wind to drive captive power consumption and reduce costs across three plants.
Kwality Pharmaceuticals revises FY27 revenue target to ₹700Cr+ and eyes ₹1,500Cr by FY30. Highlights include biosimilar expansion and 26-27% EBITDA margins.
